109 related articles for article (PubMed ID: 16647238)
1. Fuzzy role of hyperhomocysteinemia in hemodialysis patients' mortality.
Simic-Ogrizovic S; Stosovic M; Novakovic I; Pejanovic S; Jemcov T; Radovic M; Djukanovic L
Biomed Pharmacother; 2006 May; 60(4):200-7. PubMed ID: 16647238
[TBL] [Abstract][Full Text] [Related]
2. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
[TBL] [Abstract][Full Text] [Related]
3. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
4. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
5. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
6. [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis].
Sydor A; Drozdz M; Kraśniak A; Miłkowski A; Chmiel G; Małczak J; Zabawa-Hołyś S; Moskal K; Podwysocki A; Szmigielski M; Czarnecka D; Gozdecka H; Kowalczyk-Michałek M; Szczeklik A; Wiecek A; Sułowicz W
Przegl Lek; 2002; 59(12):962-7. PubMed ID: 12731367
[TBL] [Abstract][Full Text] [Related]
7. [Characteristics of hyperhomocysteinemia in dialysis patients].
Lovcić V; Kes P; Reiner Z
Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
9. Effect of anemia and hyperhomocysteinemia on mortality of patients on hemodialysis.
Anees M; Mumtaz A; Ibrahim M; Shaheen SM; Asghar A
Iran J Kidney Dis; 2010 Jan; 4(1):60-5. PubMed ID: 20081306
[TBL] [Abstract][Full Text] [Related]
10. Low total plasma homocysteine level in relation to malnutrition, inflammation, and outcome in hemodialysis patients.
Akgul A; Bilgic A; Sezer S; Arat Z; Ozdemir FN; Haberal M
J Ren Nutr; 2008 Jul; 18(4):338-46. PubMed ID: 18558298
[TBL] [Abstract][Full Text] [Related]
11. Relationship between hyperhomocysteinemia and atherosclerosis in chronic hemodialysis patients.
Taruangsri P; Ong-Ajyooth L; Ong-Ajyooth S; Chaiyasoot W; Leowattana W; Sritippayawan S; Vareesangthip K; Chanchairujira T; Vasuvattakul S; Shayakul C; Vanichakarn S
J Med Assoc Thai; 2005 Oct; 88(10):1373-81. PubMed ID: 16519382
[TBL] [Abstract][Full Text] [Related]
12. [Late nephrology referral influences on morbidity and mortality of hemodialysis patients. A provincial study].
Peña JM; Logroño JM; Pernaute R; Laviades C; Virto R; Vicente de Vera C
Nefrologia; 2006; 26(1):84-97. PubMed ID: 16649429
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.
Azadibakhsh N; Hosseini RS; Atabak S; Nateghiyan N; Golestan B; Rad AH
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):779-88. PubMed ID: 19736473
[TBL] [Abstract][Full Text] [Related]
14. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation.
Suliman M; Stenvinkel P; Qureshi AR; Kalantar-Zadeh K; Bárány P; Heimbürger O; Vonesh EF; Lindholm B
Nephrol Dial Transplant; 2007 Jan; 22(1):209-17. PubMed ID: 16982634
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus.
Suliman ME; Stenvinkel P; Bárány P; Heimbürger O; Anderstam B; Lindholm B
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients.
Jungers P; Chauveau P; Bandin O; Chadefaux B; Aupetit J; Labrunie M; Descamps-Latscha B; Kamoun P
Miner Electrolyte Metab; 1997; 23(3-6):170-3. PubMed ID: 9387110
[TBL] [Abstract][Full Text] [Related]
17. Young hemodialysis patients are exposed to hyperhomocysteinemia.
Takenaka T; Itaya Y; Suzuki H
J Ren Nutr; 2005 Oct; 15(4):435-40. PubMed ID: 16198935
[TBL] [Abstract][Full Text] [Related]
18. Low cholesterol along with inflammation predicts morbidity and mortality in hemodialysis patients.
Tsirpanlis G; Boufidou F; Zoga M; Triantafyllis G; Fatourou A; Stamatelou K; Bleta A; Petrihou C; Chatzipanagiotou S; Nicolaou C
Hemodial Int; 2009 Apr; 13(2):197-204. PubMed ID: 19432694
[TBL] [Abstract][Full Text] [Related]
19. [Alteration of homocysteine before and after hemodialysis in chronic hemodialysis patients].
Wang HT; Peng YM; Liu H
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):266-8. PubMed ID: 14653086
[TBL] [Abstract][Full Text] [Related]
20. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
House AA; Eliasziw M; Urquhart BL; Freeman DJ; Spence JD
Am J Kidney Dis; 2004 Oct; 44(4):689-94. PubMed ID: 15384020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
